Skip to main content
Premium Trial:

Request an Annual Quote

Myriad Genetics Licenses Cancer Dx Technology from Chronix

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Myriad Genetics has licensed from Chronix Biomedical the rights to technology for early detection of cancer.

The Salt Lake City-based molecular diagnostics developer said in a statement today that it has licensed rights to the technology in North America, South America, and Europe for early detection of breast, colon, and prostate cancers. It will pay San Jose, Calif.-based Chronix upfront fees, milestone payments, and royalties based on technical and commercial success of the products.

Chronix's technology uses disease-specific biomarkers based on DNA fragments from damaged and dying cells that circulate in the bloodstream and are applicable to a range of cancers and other diseases. According to Myriad, a study of 575 individuals that was presented at the American Society of Clinical Oncology showed that Chronix's technology had 92 percent sensitivity and 100 percent specificity in indicating the presence of prostate or breast cancer.

"The technology we have licensed from Chronix Biomedical has the potential to revolutionize the early detection of cancer through the analysis of unique DNA sequences in blood samples," Mark Capone, president of Myriad Genetic Laboratories, said. "This acquisition is consistent with our strategy to broaden our preventive care portfolio beyond predictive medicine products for women's health, and supply healthcare providers with enhanced tools to catch disease early, when it is most treatable."

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.